356 related articles for article (PubMed ID: 15939809)
21. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.
Walcher D; Hess K; Heinz P; Petscher K; Vasic D; Kintscher U; Clemenz M; Hartge M; Raps K; Hombach V; Marx N
Hypertension; 2008 Feb; 51(2):259-66. PubMed ID: 18158351
[TBL] [Abstract][Full Text] [Related]
22. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats.
Muñoz MC; Giani JF; Dominici FP; Turyn D; Toblli JE
J Hypertens; 2009 Dec; 27(12):2409-20. PubMed ID: 19901849
[TBL] [Abstract][Full Text] [Related]
23. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
[TBL] [Abstract][Full Text] [Related]
24. Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation.
Müller-Fielitz H; Landolt J; Heidbreder M; Werth S; Vogt FM; Jöhren O; Raasch W
Endocrinology; 2012 Mar; 153(3):1103-15. PubMed ID: 22253423
[TBL] [Abstract][Full Text] [Related]
25. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
[TBL] [Abstract][Full Text] [Related]
26. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
[TBL] [Abstract][Full Text] [Related]
27. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.
Hu ZP; Fang XL; Qian HY; Fang N; Wang BN; Wang Y
Fundam Clin Pharmacol; 2014 Oct; 28(5):501-11. PubMed ID: 24188213
[TBL] [Abstract][Full Text] [Related]
28. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
[TBL] [Abstract][Full Text] [Related]
29. Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats.
Muñoz MC; Argentino DP; Dominici FP; Turyn D; Toblli JE
J Hypertens; 2006 Aug; 24(8):1607-17. PubMed ID: 16877964
[TBL] [Abstract][Full Text] [Related]
30. Valsartan, independently of AT1 receptor or PPARγ, suppresses LPS-induced macrophage activation and improves insulin resistance in cocultured adipocytes.
Iwashita M; Sakoda H; Kushiyama A; Fujishiro M; Ohno H; Nakatsu Y; Fukushima T; Kumamoto S; Tsuchiya Y; Kikuchi T; Kurihara H; Akazawa H; Komuro I; Kamata H; Nishimura F; Asano T
Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E286-96. PubMed ID: 22045314
[TBL] [Abstract][Full Text] [Related]
31. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
[TBL] [Abstract][Full Text] [Related]
32. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF
Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099
[TBL] [Abstract][Full Text] [Related]
33. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
Matsumura T; Kinoshita H; Ishii N; Fukuda K; Motoshima H; Senokuchi T; Taketa K; Kawasaki S; Nishimaki-Mogami T; Kawada T; Nishikawa T; Araki E
Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1268-75. PubMed ID: 21474824
[TBL] [Abstract][Full Text] [Related]
34. Irbesartan enhances GLUT4 translocation and glucose transport in skeletal muscle cells.
Kobayashi T; Akiyama Y; Akiyama N; Katoh H; Yamamoto S; Funatsuki K; Yanagimoto T; Notoya M; Asakura K; Shinosaki T; Hanasaki K
Eur J Pharmacol; 2010 Dec; 649(1-3):23-8. PubMed ID: 20826135
[TBL] [Abstract][Full Text] [Related]
35. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Yamada S; Ano N; Toda K; Kitaoka A; Shiono K; Inoue G; Atsuda K; Irie J
Hypertens Res; 2008 Apr; 31(4):601-6. PubMed ID: 18633170
[TBL] [Abstract][Full Text] [Related]
36. Effects of telmisartan on TNFα induced PPARγ phosphorylation and insulin resistance in adipocytes.
Fang T; Di Y; Li G; Cui X; Shen N; Li Y; Xi P; Xie Y; Tian F; Li G
Biochem Biophys Res Commun; 2018 Sep; 503(4):3044-3049. PubMed ID: 30143256
[TBL] [Abstract][Full Text] [Related]
37. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action.
Ishiguro H; Ishiguro Y; Kubota Y; Uemura H
Prostate; 2007 Jun; 67(9):924-32. PubMed ID: 17440964
[TBL] [Abstract][Full Text] [Related]
38. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Benson SC; Pershadsingh HA; Ho CI; Chittiboyina A; Desai P; Pravenec M; Qi N; Wang J; Avery MA; Kurtz TW
Hypertension; 2004 May; 43(5):993-1002. PubMed ID: 15007034
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin inhibition stimulates PPARgamma and the release of visfatin.
Storka A; Vojtassakova E; Mueller M; Kapiotis S; Haider DG; Jungbauer A; Wolzt M
Eur J Clin Invest; 2008 Nov; 38(11):820-6. PubMed ID: 19021699
[TBL] [Abstract][Full Text] [Related]
40. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.
Zhang J; Liu X; Wang SQ; Liu GY; Xu WR; Cheng XC; Wang RL
J Biomol Struct Dyn; 2017 Sep; 35(12):2665-2680. PubMed ID: 27602589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
